Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone for irritability associated with autistic disorder in children and adolescents
2015-001320-31Phase 3
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risperidone in Autism Spectrum Disorder (ASD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in ABC-J Irritability Subscale score.
02
Drugs
risperidone
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2015-001320-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001320-31.